Synopsis
Synopsis
0
JDMF
0
KDMF
0
VMF
0
Listed Suppliers
0
FDF
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
US Medicaid
NA
Annual Reports
NA
Finished Drug Prices
NA
1. 2 Hydroxypropyl Beta Cyclodextrin
2. 2 Hydroxypropyl-beta-cyclodextrin
3. 2-hydroxypropyl-beta-cyclodextrin
4. Beta Hydroxypropylcyclodextrin
5. Beta-hydroxypropylcyclodextrin
6. Betadex, Hydroxypropyl
7. Hp-beta-cd
8. Hpbetacd
9. Hydroxypropyl Beta Cyclodextrin
10. Hydroxypropyl Betadex
11. Hydroxypropyl-beta-cyclodextrin
1. 107745-73-3
2. Hp-beta-cd
3. 2-hydroxypropyl-
4. A-cyclodextrin
5. 6a,6b,6c,6d,6e,6f,6g-heptakis-o-(2-hydroxypropyl)-beta-cyclodextrin
6. Trappsol Hpb
7. Hydroxypropylbetadex
8. Thpb
9. Hydroxypropyl-beta-cyclodextri
10. Hydroxypropyl-beta Cyclodextrin
11. Chembl577294
12. Dtxsid401017375
13. .beta.-cyclodextrin, 6a,6b,6c,6d,6e,6f,6g-heptakis-o-(2-hydroxypropyl)-
14. 6a,6b,6c,6d,6e,6f,6g-heptakis-o-(2-hydroxypropyl)-beta-cyclodextrinr
Molecular Weight | 1541.5 g/mol |
---|---|
Molecular Formula | C63H112O42 |
XLogP3 | -13 |
Hydrogen Bond Donor Count | 21 |
Hydrogen Bond Acceptor Count | 42 |
Rotatable Bond Count | 28 |
Exact Mass | 1540.6628176 g/mol |
Monoisotopic Mass | 1540.6628176 g/mol |
Topological Polar Surface Area | 619 Ų |
Heavy Atom Count | 105 |
Formal Charge | 0 |
Complexity | 2010 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 35 |
Undefined Atom Stereocenter Count | 7 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 1 |
Excipients
Usually inert substances added to a prescription in order to provide suitable consistency to the dosage form. These include binders, matrix, base or diluent in pills, tablets, creams, salves, etc. (See all compounds classified as Excipients.)
Date of Issue : 2022-07-08
Valid Till : 2024-11-04
Written Confirmation Number : WC-0432
Address of the Firm :
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 30897
Submission : 2016-08-29
Status : Active
Type : II
Certificate Number : R1-CEP 2015-264 - Rev 00
Issue Date : 2022-04-04
Type : Chemical
Substance Number : 1804
Status : Valid
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 28889
Submission : 2014-12-30
Status : Active
Type : II
Certificate Number : CEP 2022-219 - Rev 00
Issue Date : 2023-11-27
Type : Chemical
Substance Number : 1804
Status : Valid
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 28889
Submission : 2014-12-30
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 30897
Submission : 2016-08-29
Status : Active
Type : II
Hydroxypropylbetadex, MS 0.58-0.68, MS 0.81-0.99...
Certificate Number : R1-CEP 2015-264 - Rev 00
Status : Valid
Issue Date : 2022-04-04
Type : Chemical
Substance Number : 1804
Hydroxypropylbetadex, Molar Substitution (MS) 0....
Certificate Number : CEP 2022-219 - Rev 00
Status : Valid
Issue Date : 2023-11-27
Type : Chemical
Substance Number : 1804
Hydroxypropyl Betadex BP/USP/EP
Date of Issue : 2022-07-08
Valid Till : 2024-11-04
Written Confirmation Number : WC-0432
Address of the Firm : Plot No N·5, MIDC, Boisar, Tal Palghar, Dist- Thane, 401506, Maharashtra
NDC Package Code : 73212-043
Start Marketing Date : 2022-01-03
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1g/g)
Marketing Category : BULK INGREDIENT
Details:
The combined company will focus on the development of Trappsol Cyclo (hydroxypropyl-beta cyclodextrin) for the treatment of Niemann-Pick Disease Type C1.
Lead Product(s): Hydroxypropyl-Beta Cyclodextrin
Therapeutic Area: Rare Diseases and Disorders Brand Name: Trappsol Cyclo
Study Phase: Phase IIIProduct Type: Small molecule
Sponsor: Cyclo Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Merger August 22, 2024
Lead Product(s) : Hydroxypropyl-Beta Cyclodextrin
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Cyclo Therapeutics
Deal Size : Undisclosed
Deal Type : Merger
Rafael Holdings and Cyclo Therapeutics Enter Into a Definitive Merger Agreement
Details : The combined company will focus on the development of Trappsol Cyclo (hydroxypropyl-beta cyclodextrin) for the treatment of Niemann-Pick Disease Type C1.
Brand Name : Trappsol Cyclo
Molecule Type : Small molecule
Upfront Cash : Undisclosed
August 22, 2024
Details:
Trappsol Cyclo (hydroxypropyl betacyclodextrin) is being evaluated for the treatment of systemic and neurological symptoms of Niemann-Pick Disease Type C1.
Lead Product(s): Hydroxypropyl-Beta Cyclodextrin
Therapeutic Area: Rare Diseases and Disorders Brand Name: Trappsol Cyclo
Study Phase: Phase IIIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 30, 2024
Lead Product(s) : Hydroxypropyl-Beta Cyclodextrin
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Cyclo Therapeutics Completes Enrollment in Phase 3 TransportNPC™ Trial
Details : Trappsol Cyclo (hydroxypropyl betacyclodextrin) is being evaluated for the treatment of systemic and neurological symptoms of Niemann-Pick Disease Type C1.
Brand Name : Trappsol Cyclo
Molecule Type : Small molecule
Upfront Cash : Not Applicable
May 30, 2024
Details:
VAR 200 (2-hydroxypropyl-beta-cyclodextrin) is being developed to mediate removal of excess cholesterol that damages the kidneys’ filtration system in patients with Diabetic Kidney Disease.
Lead Product(s): Hydroxypropyl-Beta Cyclodextrin
Therapeutic Area: Nephrology Brand Name: VAR 200
Study Phase: Phase IProduct Type: Large molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 18, 2024
Lead Product(s) : Hydroxypropyl-Beta Cyclodextrin
Therapeutic Area : Nephrology
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
ZyVersa Gets IRB Approval for Phase 2a Trial Of VAR 200 in Diabetic Kidney Disease
Details : VAR 200 (2-hydroxypropyl-beta-cyclodextrin) is being developed to mediate removal of excess cholesterol that damages the kidneys’ filtration system in patients with Diabetic Kidney Disease.
Brand Name : VAR 200
Molecule Type : Large molecule
Upfront Cash : Not Applicable
March 18, 2024
Details:
The combined company will focus on advancing Cyclo Therapeutics’ pivotal Phase 3 global study evaluating Trappsol Cyclo (hydroxypropyl beta cyclodextrin), an orphan drug designated product in the United States and Europe, for Niemann-Pick Disease Type C1 (NPC1).
Lead Product(s): Hydroxypropyl-Beta Cyclodextrin
Therapeutic Area: Rare Diseases and Disorders Brand Name: Trappsol Cyclo
Study Phase: Phase IIIProduct Type: Large molecule
Sponsor: Cyclo Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Merger December 27, 2023
Lead Product(s) : Hydroxypropyl-Beta Cyclodextrin
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Cyclo Therapeutics
Deal Size : Undisclosed
Deal Type : Merger
Cyclo Therapeutics, Inc. Completes Merger with Applied Molecular Transport Inc.
Details : The combined company will focus on advancing Cyclo Therapeutics’ pivotal Phase 3 global study evaluating Trappsol Cyclo (hydroxypropyl beta cyclodextrin), an orphan drug designated product in the United States and Europe, for Niemann-Pick Disease Type ...
Brand Name : Trappsol Cyclo
Molecule Type : Large molecule
Upfront Cash : Undisclosed
December 27, 2023
Details:
Trappsol Cyclo is a proprietary formulation of hydroxypropyl beta cyclodextrin being developed in phase 3 clinical trials for the potential treatment of Niemann-Pick Disease Type C1, a rare and fatal genetic disease.
Lead Product(s): Hydroxypropyl-Beta Cyclodextrin
Therapeutic Area: Rare Diseases and Disorders Brand Name: Trappsol Cyclo
Study Phase: Phase IIIProduct Type: Large molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 18, 2023
Lead Product(s) : Hydroxypropyl-Beta Cyclodextrin
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Trappsol Cyclo is a proprietary formulation of hydroxypropyl beta cyclodextrin being developed in phase 3 clinical trials for the potential treatment of Niemann-Pick Disease Type C1, a rare and fatal genetic disease.
Brand Name : Trappsol Cyclo
Molecule Type : Large molecule
Upfront Cash : Not Applicable
December 18, 2023
Details:
VAR 200 (2-hydroxypropyl-beta-cyclodextrin, 2HPβCD) is a phase 2a-ready drug in development which has potential to treat multiple kidney diseases, including diabetic kidney disease, rare kidney diseases, FSGS (focal segmental glomerulosclerosis) and Alport syndrome.
Lead Product(s): Hydroxypropyl-Beta Cyclodextrin
Therapeutic Area: Nephrology Brand Name: VAR 200
Study Phase: Phase IProduct Type: Large molecule
Sponsor: George Clinical
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 14, 2023
Lead Product(s) : Hydroxypropyl-Beta Cyclodextrin
Therapeutic Area : Nephrology
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : George Clinical
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : VAR 200 (2-hydroxypropyl-beta-cyclodextrin, 2HPβCD) is a phase 2a-ready drug in development which has potential to treat multiple kidney diseases, including diabetic kidney disease, rare kidney diseases, FSGS (focal segmental glomerulosclerosis) and Alp...
Brand Name : VAR 200
Molecule Type : Large molecule
Upfront Cash : Not Applicable
December 14, 2023
Details:
The combined company will focus on advancing Cyclo Therapeutics’ pivotal Phase 3 global study evaluating Trappsol Cyclo (hydroxypropyl beta cyclodextrin), an orphan drug designated product in the United States and Europe, for Niemann-Pick Disease Type C1 (NPC1).
Lead Product(s): Hydroxypropyl-Beta Cyclodextrin
Therapeutic Area: Rare Diseases and Disorders Brand Name: Trappsol Cyclo
Study Phase: Phase IIIProduct Type: Large molecule
Sponsor: Cyclo Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Merger September 21, 2023
Lead Product(s) : Hydroxypropyl-Beta Cyclodextrin
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Cyclo Therapeutics
Deal Size : Undisclosed
Deal Type : Merger
Details : The combined company will focus on advancing Cyclo Therapeutics’ pivotal Phase 3 global study evaluating Trappsol Cyclo (hydroxypropyl beta cyclodextrin), an orphan drug designated product in the United States and Europe, for Niemann-Pick Disease Type ...
Brand Name : Trappsol Cyclo
Molecule Type : Large molecule
Upfront Cash : Undisclosed
September 21, 2023
Details:
Cyclo Therapeutics intends to use the proceeds to support of its Trappsol Cyclo, a proprietary formulation of hydroxypropyl beta cyclodextrin being developed in clinical trials for the potential treatment of Niemann-Pick Disease Type C1, a rare, fatal and Alzheimer’s disease.
Lead Product(s): Hydroxypropyl-Beta Cyclodextrin
Therapeutic Area: Rare Diseases and Disorders Brand Name: Trappsol Cyclo
Study Phase: Phase IIIProduct Type: Large molecule
Sponsor: Rafael Holdings
Deal Size: $5.0 million Upfront Cash: Undisclosed
Deal Type: Private Placement August 02, 2023
Lead Product(s) : Hydroxypropyl-Beta Cyclodextrin
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Rafael Holdings
Deal Size : $5.0 million
Deal Type : Private Placement
Cyclo Therapeutics Announces Closing of $5.0 Million Private Placement with Rafael Holdings, Inc.
Details : Cyclo Therapeutics intends to use the proceeds to support of its Trappsol Cyclo, a proprietary formulation of hydroxypropyl beta cyclodextrin being developed in clinical trials for the potential treatment of Niemann-Pick Disease Type C1, a rare, fatal an...
Brand Name : Trappsol Cyclo
Molecule Type : Large molecule
Upfront Cash : Undisclosed
August 02, 2023
Details:
Cyclo Therapeutics intends to use the proceeds for the support of its Trappsol Cyclo (hydroxypropyl beta cyclodextrin), an orphan drug designated product in the United States and Europe, under clinical trial for Niemann-Pick Disease Type C, a rare and fatal genetic disease.
Lead Product(s): Hydroxypropyl-Beta Cyclodextrin
Therapeutic Area: Rare Diseases and Disorders Brand Name: Trappsol Cyclo
Study Phase: Phase IIIProduct Type: Large molecule
Sponsor: Rafael Holdings
Deal Size: $5.0 million Upfront Cash: Undisclosed
Deal Type: Private Placement June 05, 2023
Lead Product(s) : Hydroxypropyl-Beta Cyclodextrin
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Rafael Holdings
Deal Size : $5.0 million
Deal Type : Private Placement
Details : Cyclo Therapeutics intends to use the proceeds for the support of its Trappsol Cyclo (hydroxypropyl beta cyclodextrin), an orphan drug designated product in the United States and Europe, under clinical trial for Niemann-Pick Disease Type C, a rare and fa...
Brand Name : Trappsol Cyclo
Molecule Type : Large molecule
Upfront Cash : Undisclosed
June 05, 2023
Details:
Trappsol® Cyclo™ (hydroxypropyl beta cyclodextrin), effectively manages the transportation of cholesterol accumulated out of the cells by taking the place of the defective NPC1 protein. It is currently being evaluated for Early Alzheimer’s Disease and NPC1.
Lead Product(s): Hydroxypropyl-Beta Cyclodextrin
Therapeutic Area: Rare Diseases and Disorders Brand Name: Trappsol Cyclo
Study Phase: Phase IIIProduct Type: Large molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 11, 2023
Lead Product(s) : Hydroxypropyl-Beta Cyclodextrin
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Cyclo Therapeutics Provides Clinical Program Update and Highlights Recent Achievements
Details : Trappsol® Cyclo™ (hydroxypropyl beta cyclodextrin), effectively manages the transportation of cholesterol accumulated out of the cells by taking the place of the defective NPC1 protein. It is currently being evaluated for Early Alzheimer’s Disease a...
Brand Name : Trappsol Cyclo
Molecule Type : Large molecule
Upfront Cash : Not Applicable
January 11, 2023
Market Place
Reply
30 Oct 2018
Reply
01 Apr 2017
Reply
16 Jan 2021
REF. STANDARDS & IMPURITIES
Hydroxypropyl Betadex (200 mg)
CAS Number : 128446-35-5
Quantity Per Vial : 200
Sale Unit : mg
Price : $275.00
Details : USMCA- No; KORUS- No
Monograph :
Storage :
Code/Batch No : Catalog #1329709
ABOUT THIS PAGE
A Hydroxypropyl-Beta Cyclodextrin manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Hydroxypropyl-Beta Cyclodextrin, including repackagers and relabelers. The FDA regulates Hydroxypropyl-Beta Cyclodextrin manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Hydroxypropyl-Beta Cyclodextrin API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A Hydroxypropyl-Beta Cyclodextrin supplier is an individual or a company that provides Hydroxypropyl-Beta Cyclodextrin active pharmaceutical ingredient (API) or Hydroxypropyl-Beta Cyclodextrin finished formulations upon request. The Hydroxypropyl-Beta Cyclodextrin suppliers may include Hydroxypropyl-Beta Cyclodextrin API manufacturers, exporters, distributors and traders.
click here to find a list of Hydroxypropyl-Beta Cyclodextrin suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Hydroxypropyl-Beta Cyclodextrin DMF (Drug Master File) is a document detailing the whole manufacturing process of Hydroxypropyl-Beta Cyclodextrin active pharmaceutical ingredient (API) in detail. Different forms of Hydroxypropyl-Beta Cyclodextrin DMFs exist exist since differing nations have different regulations, such as Hydroxypropyl-Beta Cyclodextrin USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Hydroxypropyl-Beta Cyclodextrin DMF submitted to regulatory agencies in the US is known as a USDMF. Hydroxypropyl-Beta Cyclodextrin USDMF includes data on Hydroxypropyl-Beta Cyclodextrin's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Hydroxypropyl-Beta Cyclodextrin USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Hydroxypropyl-Beta Cyclodextrin suppliers with USDMF on PharmaCompass.
A Hydroxypropyl-Beta Cyclodextrin CEP of the European Pharmacopoeia monograph is often referred to as a Hydroxypropyl-Beta Cyclodextrin Certificate of Suitability (COS). The purpose of a Hydroxypropyl-Beta Cyclodextrin CEP is to show that the European Pharmacopoeia monograph adequately controls the purity of Hydroxypropyl-Beta Cyclodextrin EP produced by a given manufacturer. Suppliers of raw materials can prove the suitability of Hydroxypropyl-Beta Cyclodextrin to their clients by showing that a Hydroxypropyl-Beta Cyclodextrin CEP has been issued for it. The manufacturer submits a Hydroxypropyl-Beta Cyclodextrin CEP (COS) as part of the market authorization procedure, and it takes on the role of a Hydroxypropyl-Beta Cyclodextrin CEP holder for the record. Additionally, the data presented in the Hydroxypropyl-Beta Cyclodextrin CEP (COS) is managed confidentially and offers a centralized system acknowledged by numerous nations, exactly like the Hydroxypropyl-Beta Cyclodextrin DMF.
A Hydroxypropyl-Beta Cyclodextrin CEP (COS) is recognised by all 36 nations that make up the European Pharmacopoeia Convention. Hydroxypropyl-Beta Cyclodextrin CEPs may be accepted in nations that are not members of the Ph. Eur. at the discretion of the authorities there.
click here to find a list of Hydroxypropyl-Beta Cyclodextrin suppliers with CEP (COS) on PharmaCompass.
A Hydroxypropyl-Beta Cyclodextrin written confirmation (Hydroxypropyl-Beta Cyclodextrin WC) is an official document issued by a regulatory agency to a Hydroxypropyl-Beta Cyclodextrin manufacturer, verifying that the manufacturing facility of a Hydroxypropyl-Beta Cyclodextrin active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Hydroxypropyl-Beta Cyclodextrin APIs or Hydroxypropyl-Beta Cyclodextrin finished pharmaceutical products to another nation, regulatory agencies frequently require a Hydroxypropyl-Beta Cyclodextrin WC (written confirmation) as part of the regulatory process.
click here to find a list of Hydroxypropyl-Beta Cyclodextrin suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Hydroxypropyl-Beta Cyclodextrin as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Hydroxypropyl-Beta Cyclodextrin API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Hydroxypropyl-Beta Cyclodextrin as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Hydroxypropyl-Beta Cyclodextrin and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Hydroxypropyl-Beta Cyclodextrin NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Hydroxypropyl-Beta Cyclodextrin suppliers with NDC on PharmaCompass.
Hydroxypropyl-Beta Cyclodextrin Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Hydroxypropyl-Beta Cyclodextrin GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Hydroxypropyl-Beta Cyclodextrin GMP manufacturer or Hydroxypropyl-Beta Cyclodextrin GMP API supplier for your needs.
A Hydroxypropyl-Beta Cyclodextrin CoA (Certificate of Analysis) is a formal document that attests to Hydroxypropyl-Beta Cyclodextrin's compliance with Hydroxypropyl-Beta Cyclodextrin specifications and serves as a tool for batch-level quality control.
Hydroxypropyl-Beta Cyclodextrin CoA mostly includes findings from lab analyses of a specific batch. For each Hydroxypropyl-Beta Cyclodextrin CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Hydroxypropyl-Beta Cyclodextrin may be tested according to a variety of international standards, such as European Pharmacopoeia (Hydroxypropyl-Beta Cyclodextrin EP), Hydroxypropyl-Beta Cyclodextrin JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Hydroxypropyl-Beta Cyclodextrin USP).
LOOKING FOR A SUPPLIER?